Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. (Nasdaq: AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors, and its news flow reflects this specialization. Company announcements emphasize progress in its miniprotein radioconjugate platform, which is designed to deliver radioisotopes selectively to tumors while limiting exposure to normal tissues.
News related to Aktis Oncology includes capital markets milestones, such as the closing of its upsized initial public offering and the start of trading on the Nasdaq Global Select Market under the AKTS ticker. These updates provide context on how the company is financing its research and development activities in targeted alpha radiopharmaceuticals.
Investors and observers can also expect coverage of pipeline developments. Aktis Oncology has highlighted programs such as AKY-1189 and AKY-2519, as well as its most advanced program targeting Nectin-4 with a miniprotein radioconjugate that it describes as having multi-indication potential across multiple tumor types. News may discuss clinical progress, platform refinements, and efforts to expand the reach of its radiopharmaceutical candidates to larger patient populations.
Another recurring theme in Aktis Oncology news is its strategic collaboration with Eli Lilly and Company, which is intended to apply the company’s miniprotein platform to novel radioconjugates outside its proprietary pipeline. Updates may reference how this collaboration fits into the company’s broader strategy.
For readers following AKTS, the news page offers a way to track developments in its clinical programs, financing events, and partnership activities over time. Regularly reviewing this coverage can help provide a clearer picture of how the company’s radiopharmaceutical platform and solid tumor pipeline are evolving.
Akoustis Technologies, Inc. (NASDAQ: AKTS) has appointed Michelle L. Petock to its board of directors, expanding the board to eight members. Petock, with 25 years of experience in finance and law, will contribute to the Strategic Development and Audit Committees. Co-Chairman Jerry Neal praised her extensive skills as a significant asset. During the December 2022 quarter, Akoustis reported strong demand for its 5G mobile and Wi-Fi products, with advancements in production capacity at its New York facility expected to reach 0.5 billion filters annually.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced on March 8, 2023, that Founder and CEO Jeff Shealy will attend the 35th Annual Roth Conference in Laguna Nigel, CA, from March 12-14, 2023. Investors can schedule meetings with management through their Roth representative. The company continues to see strong demand for Wi-Fi and 5G products, including its patented XBAW filters and new RFMi resonator solutions. Akoustis is ramping up production capacity at its New York facility to meet increasing orders, targeting 0.5 billion filters annually. Over 20 design wins have been achieved for its XBAW filters, crucial for mobile communications.
Akoustis Technologies (NASDAQ: AKTS) reported a record revenue of $5.9 million for the fiscal quarter ending December 31, 2022, marking a 59% year-over-year increase. The company anticipates further growth, projecting a sequential revenue increase of 20%-40% in the March quarter, driven by strong demand for its XBAW filter products in various markets including 5G and Wi-Fi. With the recent acquisition of GDSI and efforts to expand manufacturing in New York, Akoustis aims to leverage the CHIPS and Science Act of 2022. The company reported a net loss of $11.2 million for the quarter, with an operating loss of $12.9 million.
Akoustis Technologies, Inc. (NASDAQ: AKTS) will webcast its Q2 FY23 results on February 7, 2023, at 8:00 AM ET, followed by a Q&A session. The company continues to see strong demand for its Wi-Fi, 5G mobile, and infrastructure products, including its patented XBAW® filters. In Q2, they shipped 5G XBAW® wafers featuring advanced wafer-level packaging technology. Akoustis is ramping up production capacity at its New York facility to reach approximately 0.5 billion filters annually. With over 20 customer design wins, the firm is well-positioned for growth in the expanding RF filter market.
Akoustis Technologies has successfully closed an oversubscribed public offering, raising approximately $32 million by offering 12,545,454 shares at $2.75 each. The offering included a participation of over $1 million from management, notably a $900K investment from founder and CEO Jeff Shealy. The funds are designated for operations, business growth, capital expenditures, and R&D, alongside servicing outstanding debt. The offering was managed by B. Riley Securities, with additional management from Craig-Hallum Capital Group and Roth Capital Partners.
Akoustis aims to leverage these funds to enhance its manufacturing capabilities and capitalize on growth opportunities in the RF filter market.
Akoustis Technologies, Inc. (Nasdaq: AKTS) has announced the pricing of its underwritten public offering of 10,909,091 shares of common stock at $2.75 per share, aiming for gross proceeds of approximately $30 million. After underwriting discounts, net proceeds are expected to be around $28.2 million. Funds will support operations, capital expenditures, R&D, and potential strategic transactions. The offering's expected closing date is January 24, 2023, with a 30-day option for underwriters to purchase an additional 1,636,363 shares. B. Riley Securities is the book-running manager for this offering.
Akoustis Technologies, Inc. (NASDAQ: AKTS) has announced its first high-volume purchase order for a 5G mobile filter from a major Tier-1 RF component customer. This filter, manufactured using the XBAW® process, will be integrated into a multiplexer designed for 5G mobile devices, expected to ship in the first half of 2023. Akoustis's new wafer-level-package (WLP), developed in New York, addresses challenges in 5G and Wi-Fi coexistence. The company anticipates increased production capacity, aiming for approximately 0.5 billion filters annually. This order signifies strong demand and a robust sales funnel for Akoustis's RF filter solutions.
Akoustis Technologies (Nasdaq: AKTS) announced its intention to conduct an underwritten public offering of common stock, with plans to grant underwriters a 30-day option for additional shares. The offering's details, including size and terms, remain subject to market conditions. Proceeds from the offering will fund operations, including capital expenditures, research, debt servicing, and general corporate purposes. B. Riley Securities, Inc. acts as the sole book-running manager, with additional co-managers involved. A shelf registration statement for the offering is effective, with further details available in a forthcoming prospectus.
Akoustis Technologies has announced the acquisition of Grinding and Dicing Services (GDSI) for $20 million, comprising $14 million in cash, $2 million in stock, and a $4 million promissory note. This acquisition is immediately accretive, adding a high-margin premium services business that supports over 250 customers. The move aligns with Akoustis' strategy to reshore its semiconductor packaging capabilities under the CHIPS Act. GDSI will enhance rapid prototyping for Akoustis' XBAW filters and integrates the supply chain for national security applications.
Akoustis Technologies, Inc. (NASDAQ: AKTS) has achieved a milestone by securing its first design win in the 5G mobile sector from a leading Tier-1 RF component customer. The newly designed XBAW® RF filter will be integrated into a multiplexer for 5G mobile handsets, expected to ship in the first half of 2023. This filter utilizes a proprietary wafer-level package developed in Akoustis' New York facility, enhancing manufacturing efficiency. The company anticipates further applications for its XBAW® technology across various mobile devices and is ramping up production capacity to meet strong demand.